Filing Overview
This Form 8-K was filed by Priveterra Acquisition Corp., not AEON Biopharma, Inc., and reports events dated February 11, 2021; the filing was signed February 18, 2021. Priveterra is a special purpose acquisition company (SPAC) seeking a business combination.
Key Financial and Capitalization Metrics
- IPO: 27,600,000 units sold at $10.00 per unit, generating gross proceeds of $276.0 million.
- Each unit consisted of one Class A common share and one-third of a redeemable warrant. Each whole warrant is exercisable at $11.50 per share, subject to adjustment.
- Private placement: 5,213,333 warrants sold to Priveterra Sponsor, LLC at $1.50 per warrant, generating $7.82 million of gross proceeds.
- $276.0 million was deposited into a U.S.-based trust account at J.P. Morgan Chase Bank, N.A. The amount comprised $270.48 million of IPO proceeds, including $9.66 million of deferred underwriting commissions, and $5.52 million of private-placement proceeds.
- The filing does not provide revenue, operating profit, net income, cash flow, margins, or working-capital metrics.
Material Changes and Financing Arrangements
- Priveterra issued an unsecured convertible promissory note to its sponsor, allowing borrowings of up to $1.5 million for ongoing expenses and business-combination costs.
- Outstanding principal is due on the earlier of February 11, 2023, or the effective date of a qualifying business combination.
- The sponsor may convert outstanding amounts into warrants at $1.50 per warrant. Each resulting warrant would entitle the holder to purchase one Class A common share at $11.50 per share, subject to applicable adjustments.
- The note constitutes a direct financial obligation and was issued under the Section 4(a)(2) exemption from Securities Act registration.
Outlook, Risks, and Unusual Items
- Funds in the trust account are intended to support the eventual business combination, subject to the SPAC’s governing terms and applicable shareholder redemption rights; the filing does not describe a specific target or transaction.
- The sponsor note creates potential dilution through warrant conversion and involves related parties. The filing states that the chief executive officer, chief financial officer, and president are managers of the sponsor.
- The deferred underwriting commission of $9.66 million is included in the IPO proceeds calculation but is not described here as immediately paid.
- The filing includes an audited balance sheet as of February 11, 2021, but the supplied text does not provide its detailed balance-sheet figures.
Investor Verification Items
- Confirm the correct registrant and whether this filing is relevant to AEON Biopharma, Inc.; the supplied filing identifies Priveterra Acquisition Corp.
- Review the audited February 11, 2021 balance sheet and trust-account agreement for cash, liabilities, deferred fees, and restrictions on funds.
- Review the Sponsor Convertible Note for conversion mechanics, dilution, permitted borrowings, and maturity provisions.
- Verify the terms of any subsequent business combination, shareholder redemptions, warrant adjustments, and release of trust funds.
- Confirm the filing-date inconsistency: the report references a February 15, 2021 note issuance while the stated report date is February 11, 2021.